Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Etanercept (Enbrel) for Juvenile Myelomonocytic Leukemia

This study has been terminated.
(Slow enrollment; study terminated.)
Information provided by (Responsible Party):
M.D. Anderson Cancer Center Identifier:
First received: July 27, 2007
Last updated: August 1, 2012
Last verified: August 2012
Results First Received: August 31, 2009  
Study Type: Interventional
Study Design: Allocation: Non-Randomized;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: Leukemia
Intervention: Drug: Etanercept

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Recruitment Period: 05/19/04 through 03/05/09. All participants recruited at UT MD Anderson Cancer Center.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Study was terminated due to low accrual.

Reporting Groups
Etanercept 0.8 mg/kg subcutaneously weekly for 90 days

Participant Flow:   Overall Study
Adverse Event                1 

  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
Etanercept 0.8 mg/kg subcutaneously weekly for 90 days

Baseline Measures
Overall Participants Analyzed 
[Units: Participants]
[Units: Years]
Mean (Full Range)
 (3 to 3) 
[Units: Participants]
Female   0 
Male   1 
Region of Enrollment 
[Units: Participants]
United States   1 

  Outcome Measures

1.  Primary:   Patient Response   [ Time Frame: 12 weeks ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
Early termination due to low accrual. Rare disease with less than 100 cases diagnosed per year.

  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.

Results Point of Contact:  
Name/Title: Robert J. Wells, MD / Professor
Organization: UT MD Anderson Cancer Center
phone: 713-792-6620

Responsible Party: M.D. Anderson Cancer Center Identifier: NCT00509600     History of Changes
Other Study ID Numbers: 2004-0215
Study First Received: July 27, 2007
Results First Received: August 31, 2009
Last Updated: August 1, 2012